ˈɛfɐlˌɪzjuːmˌæb tɹˈeɪd nˈeɪm ɹˈæptɪvə, dʒˈɛnəntˌɛk, mˈɜːk səɹˈoʊnoʊ ɪz ɐ fˈɔːɹmɚli ɐvˈeɪləbəl mˌɛdɪkˈeɪʃən dɪzˈaɪnd tə tɹˈiːt ˌɔːɾoʊɪmjˈuːn dɪzˈiːzᵻz, ɚɹˈɪdʒɪnəli mˈɑːɹkɪɾᵻd tə tɹˈiːt sˌoːɹɪˈɑːsiz.
Efalizumab (trade name Raptiva, Genentech, Merck Serono) is a formerly available medication designed to treat autoimmune diseases, originally marketed to treat psoriasis.